Leadership Excellence & Acceleration Pathway Associate (Midwest Region)

Leadership Excellence & Acceleration Pathway Associate (Midwest Region) Employer Legend Biotech Location Chicago, IL; Detroit, Michigan; Minneapolis, Minnesota Start date Apr 10, 2026 View more categories View less categories Discipline Marketing , Sales & Service , Science/R D , Biotechnology , Market Access Required Education Associate Degree Position Type Full time Apply now Save job Click to add the job to your shortlist You need to sign in or create an account to save a job. Send job Job Details Company Job Details Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide. Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel). Our strategic partnership is designed to combine the strengths and expertise of both companies to advance the promise of an immunotherapy in the treatment of multiple myeloma. Legend Biotech is seeking a Leadership Excellence & Acceleration Pathway Associate as part of the Commercial team based Remotely (Midwest Region). Role Overview The Leadership Excellence & Acceleration Pathway (LEAP) Associate is a selective, high-impact role designed to accelerate the development of the next generation of commercial leaders at Legend Biotech. LEAP Associates participate in a structured, end-to-end commercial development experience spanning key commercial functions, paired with real accountability, senior leader exposure, and hands-on ownership of meaningful business work. The program is intentionally designed for high-potential professionals who have demonstrated strong execution, leadership maturity, and a desire to grow into broader commercial leadership roles within biotech. Unlike traditional entry-level or functional roles, LEAP Associates are positioned as enterprise-minded contributors, expected to think strategically, execute rigorously, operate across functions, and continuously elevate how work gets done, including through modern, AI-enabled ways of working. Upon successful completion, participants are expected to be ready for expanded-scope commercial roles within the organization.

Preferred Locations/Territories:

Chicago, IL Detroit, MI, Minneapolis, MN Program Overview 18-24 month structured rotational development program. Exposure across core commercial functions such as: Field Sales, Marketing, Market Access.

Embedded learning curriculum focused on:

End-to-end commercial strategy and execution. Cross-functional leadership and influence. Decision-making in complex, data-rich environments. Responsible and practical application of AI in commercial work. Ongoing mentorship, performance feedback, and senior leader engagement. (Specific rotation assignments and sequencing will be determined based on business priorities and developmental needs.) Key Responsibilities Across the program, LEAP Associates will be expected to: Drive execution by contributing to priority commercial initiatives and business-critical projects across functions. Translate strategy into action, supporting planning, analysis, and execution efforts that directly impact commercial performance. Operate cross-functionally, effectively partnering with Sales, Marketing, Market Access, Commercial Operations, and other stakeholders. Bring structure and insight to ambiguity, using data, judgment, and stakeholder input to support sound decision-making. Demonstrate ownership and accountability for outcomes—not just deliverables. Build influence without authority, navigating complex stakeholder environments with professionalism and credibility. Continuously elevate ways of working, including identifying opportunities to improve efficiency, rigor, and scalability. AI-Enabled Ways of Working A core expectation of the LEAP program is the development of applied AI fluency.

LEAP Associates will:

Leverage approved AI tools to support: Commercial analysis and insight generation. Planning and scenario evaluation. Content development and communication. Workflow efficiency and execution effectiveness. Apply AI responsibly and in alignment with company governance and standards. Identify and share best practices for integrating AI into everyday commercial work. Help translate AI-enabled capabilities to teams and stakeholders, supporting broader adoption and impact. AI is treated as a practical leadership capability, not a theoretical skillset.

Requirements Required:

Bachelor's degree. 5-7 years of professional experience. Demonstrated track record of execution, ownership, and results delivery. Strong analytical, communication, and problem-solving skills. Interest in biotech/pharma and commercial leadership pathways.

Preferred:

Experience in disciplined, performance-driven environments (e.g., military service or similarly structured settings). Exposure to commercial, operational, analytical, or customer-facing roles. Experience using data, analytics, digital tools, or AI-enabled solutions to support decision-making. Comfort working in complex, matrixed organizations.

Developmental Opportunities:

Exposure to senior leadership. Cross-functional rotations. Mentorship and coaching. Potential placement into full-time commercial roles upon program completion. #Li-SD1 #Li-Remote Please note: These benefits are offered exclusively to permanent full-time employees. Contractors are not eligible for benefits through Legend Biotech. EEO Statement It is the policy of Legend Biotech to provide equal employment opportunities without regard to actual or perceived race, color, creed, religion, national origin, ancestry, citizenship status, age, sex or gender (including pregnancy, childbirth, related medical conditions and lactation), gender identity or gender expression (including transgender status), sexual orientation, marital status, military service and veteran status, disability, genetic information, or any other protected characteristic under applicable federal, state or local laws or ordinances. Employment is at-will and may be terminated at any time with or without cause or notice by the employee or the company. For information related to our privacy notice, please review: Legend Biotech Privacy Notice . Company Legend Biotech was founded as an early-stage cell therapy company in 2014. The company was the brainchild of visionary scientists who recognized that antibody-based therapeutics could potentially treat disease and possessed the backgrounds in immunology and gene editing to take the leap. For two years, Legend Biotech, then known as the "Legend Project," operated in a room the size of a freight elevator, with the goal of creating a cell therapy for multiple myeloma, a hematological cancer that often relapses and can become refractory. The team produced nanobodies for single-domain antibody drugs and ultimately extended the half-life of the nanobodies with proprietary technologies. In 2015, Legend's scientists focused on research for chimeric antigen-receptor T-cells (CAR-T) targeting the BCMA protein, making the biotech one of the first companies in the world to engineer CAR-T cells for the BCMA protein. In 2016, investigator-initiated trials began in China. In 2017, data from the trials were presented at the American Society for Clinical Oncology (ASCO), which led to a partnership with biopharmaceutical company Janssen Biotech, Inc. to co-develop the anti-BCMA CAR-T, ciltacabtagene autoleucel (cilta-cel). Applications seeking approval of cilta-cel for the treatment of patients with RRMM are currently under regulatory review by several health authorities around the world.

CARVYKTI

™ (ciltacabtagene autoleucel) was approved by the U.S. Food and Drug Administration in February 2022 and received conditional marketing approval from the European Medicines Agency in May 2022. Today Legend Biotech is a global, commercial-stage company driven by a passion for patients. We continue to build our pipeline of cell therapy platforms, which includes CAR-T, CAR-NK, CAR-γδ T and non-gene-editing CAR technologies. Our goal is to bring hope and opportunity to patients and their families by continuing to explore unique technologies. Company info Location Somerset New Jersey United States Share this job Facebook Twitter LinkedIn Apply now Send job Apply now Save job Click to add the job to your shortlist You need to sign in or create an account to save a job. Get job alerts Create a job alert and receive personalized job recommendations straight to your inbox. Create alert Similar jobs Intern, Skeletal Conditions Business Unit (MBA/Masters) San Rafael, California Senior Medical Science Liaison, Oncology Hematology (Carolinas) Remote